Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joins GRACE to discuss molecular marker testing for advanced NSCLC for Spanish speaking patients and caregivers.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Med. Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at FL International University joined GRACE to discuss immune checkpoint inhibitors and how they can treat cancer.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss molecular marker testing for advanced NSCLC.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.

Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.

Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).

[powerpress]

Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]